In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Senate passes the Biosecure Act with implications for...Show More
🎉 Join the #1 community of podcast lovers and never miss a great podcast.
Sign up
Recommendations